{"pmid":32416069,"title":"Clinically Applicable AI System for Accurate Diagnosis, Quantitative Measurements, and Prognosis of COVID-19 Pneumonia Using Computed Tomography.","text":["Clinically Applicable AI System for Accurate Diagnosis, Quantitative Measurements, and Prognosis of COVID-19 Pneumonia Using Computed Tomography.","Many COVID-19 patients infected by SARS-CoV-2 virus develop pneumonia (called novel coronavirus pneumonia, NCP) and rapidly progress to respiratory failure. However, rapid diagnosis and identification of high-risk patients for early intervention are challenging. Using a large computed tomography (CT) database from 3,777 patients, we developed an AI system that can diagnose NCP and differentiate it from other common pneumonia and normal controls. The AI system can assist radiologists and physicians in performing a quick diagnosis especially when the health system is overloaded. Significantly, our AI system identified important clinical markers that correlated with the NCP lesion properties. Together with the clinical data, our AI system was able to provide accurate clinical prognosis that can aid clinicians to consider appropriate early clinical management and allocate resources appropriately. We have made this AI system available globally to assist the clinicians to combat COVID-19.","Cell","Zhang, Kang","Liu, Xiaohong","Shen, Jun","Li, Zhihuan","Sang, Ye","Wu, Xingwang","Zha, Yunfei","Liang, Wenhua","Wang, Chengdi","Wang, Ke","Ye, Linsen","Gao, Ming","Zhou, Zhongguo","Li, Liang","Wang, Jin","Yang, Zehong","Cai, Huimin","Xu, Jie","Yang, Lei","Cai, Wenjia","Xu, Wenqin","Wu, Shaoxu","Zhang, Wei","Jiang, Shanping","Zheng, Lianghong","Zhang, Xuan","Wang, Li","Lu, Liu","Li, Jiaming","Yin, Haiping","Wang, Winston","Li, Oulan","Zhang, Charlotte","Liang, Liang","Wu, Tao","Deng, Ruiyun","Wei, Kang","Zhou, Yong","Chen, Ting","Lau, Johnson Yiu-Nam","Fok, Manson","He, Jianxing","Lin, Tianxin","Li, Weimin","Wang, Guangyu","32416069"],"abstract":["Many COVID-19 patients infected by SARS-CoV-2 virus develop pneumonia (called novel coronavirus pneumonia, NCP) and rapidly progress to respiratory failure. However, rapid diagnosis and identification of high-risk patients for early intervention are challenging. Using a large computed tomography (CT) database from 3,777 patients, we developed an AI system that can diagnose NCP and differentiate it from other common pneumonia and normal controls. The AI system can assist radiologists and physicians in performing a quick diagnosis especially when the health system is overloaded. Significantly, our AI system identified important clinical markers that correlated with the NCP lesion properties. Together with the clinical data, our AI system was able to provide accurate clinical prognosis that can aid clinicians to consider appropriate early clinical management and allocate resources appropriately. We have made this AI system available globally to assist the clinicians to combat COVID-19."],"journal":"Cell","authors":["Zhang, Kang","Liu, Xiaohong","Shen, Jun","Li, Zhihuan","Sang, Ye","Wu, Xingwang","Zha, Yunfei","Liang, Wenhua","Wang, Chengdi","Wang, Ke","Ye, Linsen","Gao, Ming","Zhou, Zhongguo","Li, Liang","Wang, Jin","Yang, Zehong","Cai, Huimin","Xu, Jie","Yang, Lei","Cai, Wenjia","Xu, Wenqin","Wu, Shaoxu","Zhang, Wei","Jiang, Shanping","Zheng, Lianghong","Zhang, Xuan","Wang, Li","Lu, Liu","Li, Jiaming","Yin, Haiping","Wang, Winston","Li, Oulan","Zhang, Charlotte","Liang, Liang","Wu, Tao","Deng, Ruiyun","Wei, Kang","Zhou, Yong","Chen, Ting","Lau, Johnson Yiu-Nam","Fok, Manson","He, Jianxing","Lin, Tianxin","Li, Weimin","Wang, Guangyu"],"date":"2020-05-17T11:00:00Z","year":2020,"_id":"32416069","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.cell.2020.04.045","keywords":["ai","covid-19","sars-cov-2","automated diagnosis","computed tomography","deep learning","pneumonia","prognosis analysis"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1666991242651631616,"score":9.490897,"similar":[{"pmid":32427924,"title":"Artificial intelligence-enabled rapid diagnosis of patients with COVID-19.","text":["Artificial intelligence-enabled rapid diagnosis of patients with COVID-19.","For diagnosis of coronavirus disease 2019 (COVID-19), a SARS-CoV-2 virus-specific reverse transcriptase polymerase chain reaction (RT-PCR) test is routinely used. However, this test can take up to 2 d to complete, serial testing may be required to rule out the possibility of false negative results and there is currently a shortage of RT-PCR test kits, underscoring the urgent need for alternative methods for rapid and accurate diagnosis of patients with COVID-19. Chest computed tomography (CT) is a valuable component in the evaluation of patients with suspected SARS-CoV-2 infection. Nevertheless, CT alone may have limited negative predictive value for ruling out SARS-CoV-2 infection, as some patients may have normal radiological findings at early stages of the disease. In this study, we used artificial intelligence (AI) algorithms to integrate chest CT findings with clinical symptoms, exposure history and laboratory testing to rapidly diagnose patients who are positive for COVID-19. Among a total of 905 patients tested by real-time RT-PCR assay and next-generation sequencing RT-PCR, 419 (46.3%) tested positive for SARS-CoV-2. In a test set of 279 patients, the AI system achieved an area under the curve of 0.92 and had equal sensitivity as compared to a senior thoracic radiologist. The AI system also improved the detection of patients who were positive for COVID-19 via RT-PCR who presented with normal CT scans, correctly identifying 17 of 25 (68%) patients, whereas radiologists classified all of these patients as COVID-19 negative. When CT scans and associated clinical history are available, the proposed AI system can help to rapidly diagnose COVID-19 patients.","Nat Med","Mei, Xueyan","Lee, Hao-Chih","Diao, Kai-Yue","Huang, Mingqian","Lin, Bin","Liu, Chenyu","Xie, Zongyu","Ma, Yixuan","Robson, Philip M","Chung, Michael","Bernheim, Adam","Mani, Venkatesh","Calcagno, Claudia","Li, Kunwei","Li, Shaolin","Shan, Hong","Lv, Jian","Zhao, Tongtong","Xia, Junli","Long, Qihua","Steinberger, Sharon","Jacobi, Adam","Deyer, Timothy","Luksza, Marta","Liu, Fang","Little, Brent P","Fayad, Zahi A","Yang, Yang","32427924"],"abstract":["For diagnosis of coronavirus disease 2019 (COVID-19), a SARS-CoV-2 virus-specific reverse transcriptase polymerase chain reaction (RT-PCR) test is routinely used. However, this test can take up to 2 d to complete, serial testing may be required to rule out the possibility of false negative results and there is currently a shortage of RT-PCR test kits, underscoring the urgent need for alternative methods for rapid and accurate diagnosis of patients with COVID-19. Chest computed tomography (CT) is a valuable component in the evaluation of patients with suspected SARS-CoV-2 infection. Nevertheless, CT alone may have limited negative predictive value for ruling out SARS-CoV-2 infection, as some patients may have normal radiological findings at early stages of the disease. In this study, we used artificial intelligence (AI) algorithms to integrate chest CT findings with clinical symptoms, exposure history and laboratory testing to rapidly diagnose patients who are positive for COVID-19. Among a total of 905 patients tested by real-time RT-PCR assay and next-generation sequencing RT-PCR, 419 (46.3%) tested positive for SARS-CoV-2. In a test set of 279 patients, the AI system achieved an area under the curve of 0.92 and had equal sensitivity as compared to a senior thoracic radiologist. The AI system also improved the detection of patients who were positive for COVID-19 via RT-PCR who presented with normal CT scans, correctly identifying 17 of 25 (68%) patients, whereas radiologists classified all of these patients as COVID-19 negative. When CT scans and associated clinical history are available, the proposed AI system can help to rapidly diagnose COVID-19 patients."],"journal":"Nat Med","authors":["Mei, Xueyan","Lee, Hao-Chih","Diao, Kai-Yue","Huang, Mingqian","Lin, Bin","Liu, Chenyu","Xie, Zongyu","Ma, Yixuan","Robson, Philip M","Chung, Michael","Bernheim, Adam","Mani, Venkatesh","Calcagno, Claudia","Li, Kunwei","Li, Shaolin","Shan, Hong","Lv, Jian","Zhao, Tongtong","Xia, Junli","Long, Qihua","Steinberger, Sharon","Jacobi, Adam","Deyer, Timothy","Luksza, Marta","Liu, Fang","Little, Brent P","Fayad, Zahi A","Yang, Yang"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32427924","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1038/s41591-020-0931-3","locations":["thoracic"],"topics":["Diagnosis"],"weight":1,"_version_":1667352728836243456,"score":310.06885},{"pmid":32305937,"title":"Review of Artificial Intelligence Techniques in Imaging Data Acquisition, Segmentation and Diagnosis for COVID-19.","text":["Review of Artificial Intelligence Techniques in Imaging Data Acquisition, Segmentation and Diagnosis for COVID-19.","The pandemic of coronavirus disease 2019 (COVID-19) is spreading all over the world. Medical imaging such as X-ray and computed tomography (CT) plays an essential role in the global fight against COVID-19, whereas the recently emerging artificial intelligence (AI) technologies further strengthen the power of the imaging tools and help medical specialists. We hereby review the rapid responses in the community of medical imaging (empowered by AI) toward COVID-19. For example, AI-empowered image acquisition can significantly help automate the scanning procedure and also reshape the workflow with minimal contact to patients, providing the best protection to the imaging technicians. Also, AI can improve work efficiency by accurate delineation of infections in X-ray and CT images, facilitating subsequent quantification. Moreover, the computer-aided platforms help radiologists make clinical decisions, i.e., for disease diagnosis, tracking, and prognosis. In this review paper, we thus cover the entire pipeline of medical imaging and analysis techniques involved with COVID-19, including image acquisition, segmentation, diagnosis, and follow-up. We particularly focus on the integration of AI with X-ray and CT, both of which are widely used in the frontline hospitals, in order to depict the latest progress of medical imaging and radiology fighting against COVID-19.","IEEE Rev Biomed Eng","Shi, Feng","Wang, Jun","Shi, Jun","Wu, Ziyan","Wang, Qian","Tang, Zhenyu","He, Kelei","Shi, Yinghuan","Shen, Dinggang","32305937"],"abstract":["The pandemic of coronavirus disease 2019 (COVID-19) is spreading all over the world. Medical imaging such as X-ray and computed tomography (CT) plays an essential role in the global fight against COVID-19, whereas the recently emerging artificial intelligence (AI) technologies further strengthen the power of the imaging tools and help medical specialists. We hereby review the rapid responses in the community of medical imaging (empowered by AI) toward COVID-19. For example, AI-empowered image acquisition can significantly help automate the scanning procedure and also reshape the workflow with minimal contact to patients, providing the best protection to the imaging technicians. Also, AI can improve work efficiency by accurate delineation of infections in X-ray and CT images, facilitating subsequent quantification. Moreover, the computer-aided platforms help radiologists make clinical decisions, i.e., for disease diagnosis, tracking, and prognosis. In this review paper, we thus cover the entire pipeline of medical imaging and analysis techniques involved with COVID-19, including image acquisition, segmentation, diagnosis, and follow-up. We particularly focus on the integration of AI with X-ray and CT, both of which are widely used in the frontline hospitals, in order to depict the latest progress of medical imaging and radiology fighting against COVID-19."],"journal":"IEEE Rev Biomed Eng","authors":["Shi, Feng","Wang, Jun","Shi, Jun","Wu, Ziyan","Wang, Qian","Tang, Zhenyu","He, Kelei","Shi, Yinghuan","Shen, Dinggang"],"date":"2020-04-20T11:00:00Z","year":2020,"_id":"32305937","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1109/RBME.2020.2987975","topics":["Diagnosis"],"weight":1,"_version_":1666138493378625536,"score":299.09277},{"pmid":32367319,"pmcid":"PMC7197034","title":"Artificial intelligence to codify lung CT in Covid-19 patients.","text":["Artificial intelligence to codify lung CT in Covid-19 patients.","The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already assumed pandemic proportions, affecting over 100 countries in few weeks. A global response is needed to prepare health systems worldwide. Covid-19 can be diagnosed both on chest X-ray and on computed tomography (CT). Asymptomatic patients may also have lung lesions on imaging. CT investigation in patients with suspicion Covid-19 pneumonia involves the use of the high-resolution technique (HRCT). Artificial intelligence (AI) software has been employed to facilitate CT diagnosis. AI software must be useful categorizing the disease into different severities, integrating the structured report, prepared according to subjective considerations, with quantitative, objective assessments of the extent of the lesions. In this communication, we present an example of a good tool for the radiologist (Thoracic VCAR software, GE Healthcare, Italy) in Covid-19 diagnosis (Pan et al. in Radiology, 2020. https://doi.org/10.1148/radiol.2020200370). Thoracic VCAR offers quantitative measurements of the lung involvement. Thoracic VCAR can generate a clear, fast and concise report that communicates vital medical information to referring physicians. In the post-processing phase, software, thanks to the help of a colorimetric map, recognizes the ground glass and differentiates it from consolidation and quantifies them as a percentage with respect to the healthy parenchyma. AI software therefore allows to accurately calculate the volume of each of these areas. Therefore, keeping in mind that CT has high diagnostic sensitivity in identifying lesions, but not specific for Covid-19 and similar to other infectious viral diseases, it is mandatory to have an AI software that expresses objective evaluations of the percentage of ventilated lung parenchyma compared to the affected one.","Radiol Med","Belfiore, Maria Paola","Urraro, Fabrizio","Grassi, Roberta","Giacobbe, Giuliana","Patelli, Gianluigi","Cappabianca, Salvatore","Reginelli, Alfonso","32367319"],"abstract":["The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already assumed pandemic proportions, affecting over 100 countries in few weeks. A global response is needed to prepare health systems worldwide. Covid-19 can be diagnosed both on chest X-ray and on computed tomography (CT). Asymptomatic patients may also have lung lesions on imaging. CT investigation in patients with suspicion Covid-19 pneumonia involves the use of the high-resolution technique (HRCT). Artificial intelligence (AI) software has been employed to facilitate CT diagnosis. AI software must be useful categorizing the disease into different severities, integrating the structured report, prepared according to subjective considerations, with quantitative, objective assessments of the extent of the lesions. In this communication, we present an example of a good tool for the radiologist (Thoracic VCAR software, GE Healthcare, Italy) in Covid-19 diagnosis (Pan et al. in Radiology, 2020. https://doi.org/10.1148/radiol.2020200370). Thoracic VCAR offers quantitative measurements of the lung involvement. Thoracic VCAR can generate a clear, fast and concise report that communicates vital medical information to referring physicians. In the post-processing phase, software, thanks to the help of a colorimetric map, recognizes the ground glass and differentiates it from consolidation and quantifies them as a percentage with respect to the healthy parenchyma. AI software therefore allows to accurately calculate the volume of each of these areas. Therefore, keeping in mind that CT has high diagnostic sensitivity in identifying lesions, but not specific for Covid-19 and similar to other infectious viral diseases, it is mandatory to have an AI software that expresses objective evaluations of the percentage of ventilated lung parenchyma compared to the affected one."],"journal":"Radiol Med","authors":["Belfiore, Maria Paola","Urraro, Fabrizio","Grassi, Roberta","Giacobbe, Giuliana","Patelli, Gianluigi","Cappabianca, Salvatore","Reginelli, Alfonso"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32367319","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1007/s11547-020-01195-x","keywords":["artificial intelligence","sars-cov-2","structured report"],"locations":["Thoracic","Italy","Radiology","Thoracic","Thoracic"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Diagnosis"],"weight":1,"_version_":1666138496176226304,"score":291.9359},{"pmid":32339081,"title":"AI Augmentation of Radiologist Performance in Distinguishing COVID-19 from Pneumonia of Other Etiology on Chest CT.","text":["AI Augmentation of Radiologist Performance in Distinguishing COVID-19 from Pneumonia of Other Etiology on Chest CT.","Background COVID-19 and pneumonia of other etiology share similar CT characteristics, contributing to the challenges in differentiating them with high accuracy. Purpose To establish and evaluate an artificial intelligence (AI) system in differentiating COVID-19 and other pneumonia on chest CT and assess radiologist performance without and with AI assistance. Methods 521 patients with positive RT-PCR for COVID-19 and abnormal chest CT findings were retrospectively identified from ten hospitals from January 2020 to April 2020. 665 patients with non-COVID-19 pneumonia and definite evidence of pneumonia on chest CT were retrospectively selected from three hospitals between 2017 and 2019. To classify COVID-19 versus other pneumonia for each patient, abnormal CT slices were input into the EfficientNet B4 deep neural network architecture after lung segmentation, followed by two-layer fully-connected neural network to pool slices together. Our final cohort of 1,186 patients (132,583 CT slices) was divided into training, validation and test sets in a 7:2:1 and equal ratio. Independent testing was performed by evaluating model performance on separate hospitals. Studies were blindly reviewed by six radiologists without and then with AI assistance. Results Our final model achieved a test accuracy of 96% (95% CI: 90-98%), sensitivity 95% (95% CI: 83-100%) and specificity of 96% (95% CI: 88-99%) with Receiver Operating Characteristic (ROC) AUC of 0.95 and Precision-Recall (PR) AUC of 0.90. On independent testing, our model achieved an accuracy of 87% (95% CI: 82-90%), sensitivity of 89% (95% CI: 81-94%) and specificity of 86% (95% CI: 80-90%) with ROC AUC of 0.90 and PR AUC of 0.87. Assisted by the models' probabilities, the radiologists achieved a higher average test accuracy (90% vs. 85%, Delta=5, p<0.001), sensitivity (88% vs. 79%, Delta=9, p<0.001) and specificity (91% vs. 88%, Delta=3, p=0.001). Conclusion AI assistance improved radiologists' performance in distinguishing COVID-19 from non-COVID-19 pneumonia on chest CT.","Radiology","Bai, Harrison X","Wang, Robin","Xiong, Zeng","Hsieh, Ben","Chang, Ken","Halsey, Kasey","Tran, Thi My Linh","Choi, Ji Whae","Wang, Dong-Cui","Shi, Lin-Bo","Mei, Ji","Jiang, Xiao-Long","Pan, Ian","Zeng, Qiu-Hua","Hu, Ping-Feng","Li, Yi-Hui","Fu, Fei-Xian","Huang, Raymond Y","Sebro, Ronnie","Yu, Qi-Zhi","Atalay, Michael K","Liao, Wei-Hua","32339081"],"abstract":["Background COVID-19 and pneumonia of other etiology share similar CT characteristics, contributing to the challenges in differentiating them with high accuracy. Purpose To establish and evaluate an artificial intelligence (AI) system in differentiating COVID-19 and other pneumonia on chest CT and assess radiologist performance without and with AI assistance. Methods 521 patients with positive RT-PCR for COVID-19 and abnormal chest CT findings were retrospectively identified from ten hospitals from January 2020 to April 2020. 665 patients with non-COVID-19 pneumonia and definite evidence of pneumonia on chest CT were retrospectively selected from three hospitals between 2017 and 2019. To classify COVID-19 versus other pneumonia for each patient, abnormal CT slices were input into the EfficientNet B4 deep neural network architecture after lung segmentation, followed by two-layer fully-connected neural network to pool slices together. Our final cohort of 1,186 patients (132,583 CT slices) was divided into training, validation and test sets in a 7:2:1 and equal ratio. Independent testing was performed by evaluating model performance on separate hospitals. Studies were blindly reviewed by six radiologists without and then with AI assistance. Results Our final model achieved a test accuracy of 96% (95% CI: 90-98%), sensitivity 95% (95% CI: 83-100%) and specificity of 96% (95% CI: 88-99%) with Receiver Operating Characteristic (ROC) AUC of 0.95 and Precision-Recall (PR) AUC of 0.90. On independent testing, our model achieved an accuracy of 87% (95% CI: 82-90%), sensitivity of 89% (95% CI: 81-94%) and specificity of 86% (95% CI: 80-90%) with ROC AUC of 0.90 and PR AUC of 0.87. Assisted by the models' probabilities, the radiologists achieved a higher average test accuracy (90% vs. 85%, Delta=5, p<0.001), sensitivity (88% vs. 79%, Delta=9, p<0.001) and specificity (91% vs. 88%, Delta=3, p=0.001). Conclusion AI assistance improved radiologists' performance in distinguishing COVID-19 from non-COVID-19 pneumonia on chest CT."],"journal":"Radiology","authors":["Bai, Harrison X","Wang, Robin","Xiong, Zeng","Hsieh, Ben","Chang, Ken","Halsey, Kasey","Tran, Thi My Linh","Choi, Ji Whae","Wang, Dong-Cui","Shi, Lin-Bo","Mei, Ji","Jiang, Xiao-Long","Pan, Ian","Zeng, Qiu-Hua","Hu, Ping-Feng","Li, Yi-Hui","Fu, Fei-Xian","Huang, Raymond Y","Sebro, Ronnie","Yu, Qi-Zhi","Atalay, Michael K","Liao, Wei-Hua"],"date":"2020-04-28T11:00:00Z","year":2020,"_id":"32339081","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1148/radiol.2020201491","topics":["Diagnosis"],"weight":1,"_version_":1666138494257332224,"score":285.49054},{"pmid":32426387,"pmcid":"PMC7227517","title":"Artificial intelligence approach fighting COVID-19 with repurposing drugs.","text":["Artificial intelligence approach fighting COVID-19 with repurposing drugs.","Background: The ongoing COVID-19 pandemic has caused more than 193,825 deaths during the past few months. A quick-to-be-identified cure for the disease will be a therapeutic medicine that has prior use experiences in patients in order to resolve the current pandemic situation before it could become worsening. Artificial intelligence (AI) technology is hereby applied to identify the marketed drugs with potential for treating COVID-19. Material and methods: An AI platform was established to identify potential old drugs with anti-coronavirus activities by using two different learning databases; one consisted of the compounds reported or proven active against SARS-CoV, SARS-CoV-2, human immunodeficiency virus, influenza virus, and the other one containing the known 3C-like protease inhibitors. All AI predicted drugs were then tested for activities against a feline coronavirus in in vitro cell-based assay. These assay results were feedbacks to the AI system for relearning and thus to generate a modified AI model to search for old drugs again. Results: After a few runs of AI learning and prediction processes, the AI system identified 80 marketed drugs with potential. Among them, 8 drugs (bedaquiline, brequinar, celecoxib, clofazimine, conivaptan, gemcitabine, tolcapone, and vismodegib) showed in vitro activities against the proliferation of a feline infectious peritonitis (FIP) virus in Fcwf-4 cells. In addition, 5 other drugs (boceprevir, chloroquine, homoharringtonine, tilorone, and salinomycin) were also found active during the exercises of AI approaches. Conclusion: Having taken advantages of AI, we identified old drugs with activities against FIP coronavirus. Further studies are underway to demonstrate their activities against SARS-CoV-2 in vitro and in vivo at clinically achievable concentrations and doses. With prior use experiences in patients, these old drugs if proven active against SARS-CoV-2 can readily be applied for fighting COVID-19 pandemic.","Biomed J","Ke, Yi-Yu","Peng, Tzu-Ting","Yeh, Teng-Kuang","Huang, Wen-Zheng","Chang, Shao-En","Wu, Szu-Huei","Hung, Hui-Chen","Hsu, Tsu-An","Lee, Shiow-Ju","Song, Jeng-Shin","Lin, Wen-Hsing","Chiang, Tung-Jung","Lin, Jiunn-Horng","Sytwu, Huey-Kang","Chen, Chiung-Tong","32426387"],"abstract":["Background: The ongoing COVID-19 pandemic has caused more than 193,825 deaths during the past few months. A quick-to-be-identified cure for the disease will be a therapeutic medicine that has prior use experiences in patients in order to resolve the current pandemic situation before it could become worsening. Artificial intelligence (AI) technology is hereby applied to identify the marketed drugs with potential for treating COVID-19. Material and methods: An AI platform was established to identify potential old drugs with anti-coronavirus activities by using two different learning databases; one consisted of the compounds reported or proven active against SARS-CoV, SARS-CoV-2, human immunodeficiency virus, influenza virus, and the other one containing the known 3C-like protease inhibitors. All AI predicted drugs were then tested for activities against a feline coronavirus in in vitro cell-based assay. These assay results were feedbacks to the AI system for relearning and thus to generate a modified AI model to search for old drugs again. Results: After a few runs of AI learning and prediction processes, the AI system identified 80 marketed drugs with potential. Among them, 8 drugs (bedaquiline, brequinar, celecoxib, clofazimine, conivaptan, gemcitabine, tolcapone, and vismodegib) showed in vitro activities against the proliferation of a feline infectious peritonitis (FIP) virus in Fcwf-4 cells. In addition, 5 other drugs (boceprevir, chloroquine, homoharringtonine, tilorone, and salinomycin) were also found active during the exercises of AI approaches. Conclusion: Having taken advantages of AI, we identified old drugs with activities against FIP coronavirus. Further studies are underway to demonstrate their activities against SARS-CoV-2 in vitro and in vivo at clinically achievable concentrations and doses. With prior use experiences in patients, these old drugs if proven active against SARS-CoV-2 can readily be applied for fighting COVID-19 pandemic."],"journal":"Biomed J","authors":["Ke, Yi-Yu","Peng, Tzu-Ting","Yeh, Teng-Kuang","Huang, Wen-Zheng","Chang, Shao-En","Wu, Szu-Huei","Hung, Hui-Chen","Hsu, Tsu-An","Lee, Shiow-Ju","Song, Jeng-Shin","Lin, Wen-Hsing","Chiang, Tung-Jung","Lin, Jiunn-Horng","Sytwu, Huey-Kang","Chen, Chiung-Tong"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32426387","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.bj.2020.05.001","keywords":["ai","covid-19","dnn","drug repurposing","feline coronavirus","sars-cov-2"],"locations":["feline","vitro","vismodegib","vivo"],"e_drugs":["HhAntag691","Tolcapone","Homoharringtonine","salinomycin","gemcitabine","conivaptan","N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide","Chloroquine","Tilorone","brequinar","Celecoxib","bedaquiline","Clofazimine"],"topics":["Treatment"],"weight":1,"_version_":1667352728728240130,"score":283.64}]}